Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation

Author:

Khanam Farhana,Islam Md Taufiqul,Ahmmed Faisal,Ahmed Shams Uddin,Hossen Md Ismail,Rajib MdNazmul Hasan,Haque Shahinur,Biswas Prasanta Kumar,Tauheed Imam,Zaman K,Alam Ahmed NawsherORCID,Billah Mallick Masum,Monalisa Monalisa,Ashrafi Shah Ali Akbar,Rahman Mohammed ZiaurORCID,Bin Manjur Omar Hamza,Afrad Mokibul Hassan,Shamsuzzaman S M,Saleh Ahmed Abu,Sumon Mostafa Aziz,Rashed Asif,Bhuiyan Md Taufiqur Rahman,Chowdhury Fahima,Khan Ashraful Islam,Flora Meerjady Sabrina,Shirin TahminaORCID,Clemens John D.,Qadri Firdausi

Abstract

Background: From May to December 2021, Bangladesh experienced a major surge in the Delta variant of SARS-CoV-2. The earlier rollout of several vaccines offered the opportunity to evaluate vaccine effectiveness against this variant. Methods: A prospective, test-negative case-control study was conducted in five large hospitals in Dhaka between September and December 2021. The subjects were patients of at least 18 years of age who presented themselves for care, suffering COVID-like symptoms of less than 10 days’ duration. The cases had PCR-confirmed infections with SARS-CoV-2, and up to 4 PCR test-negative controls were matched to each case, according to hospital, date of presentation, and age. Vaccine protection was assessed as being the association between the receipt of a complete course of vaccine and the occurrence of SARS-CoV-2 disease, with symptoms beginning at least 14 days after the final vaccine dose. Results: In total, 313 cases were matched to 1196 controls. The genotyping of case isolates revealed 99.6% to be the Delta variant. Receipt of any vaccine was associated with 12% (95% CI: −21 to 37, p = 0.423) protection against all episodes of SARS-CoV-2. Among the three vaccines for which protection was evaluable (Moderna (mRNA-1273); Sinopharm (Vero Cell-Inactivated); Serum Institute of India (ChAdOx1 nCoV-19)), only the Moderna vaccine was associated with significant protection (64%; 95% CI: 10 to 86, p = 0.029). Protection by the receipt of any vaccine against severe disease was 85% (95% CI: 27 to 97, p = 0.019), with protection estimates of 75% to 100% for the three vaccines. Conclusions: Vaccine protection against COVID-19 disease of any severity caused by the Delta variant was modest in magnitude and significant for only one of the three evaluable vaccines. In contrast, protection against severe disease was high in magnitude and consistent for all three vaccines. Because our findings are not in complete accord with evaluations of the same vaccines in more affluent settings, our study underscores the need for country-level COVID-19 vaccine evaluations in developing countries.

Funder

Bill & Melinda Gates Foundation

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference21 articles.

1. Worldometer (2022, February 17). COVID-19 Coronavirus Pandemic. Available online: https://www.worldometers.info/coronavirus/.

2. CEPI (2022, February 17). A Leap forward in Vaccine Technology. Available online: https://cepi.net/news_cepi/a-leap-forward-in-vaccine-technology-2/.

3. Clinic, M. (2022, February 17). Comparing the Differences between COVID-19 Vaccines. Available online: https://www.mayoclinic.org/coronavirus-covid-19/vaccine/comparing-vaccines.

4. Divergent SARS-CoV-2 Omicron-reactive T-and B cell responses in COVID-19 vaccine recipients;GeurtsvanKessel;Sci. Immunol.,2022

5. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study;Li;Emerg. Microbes Infect.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3